• OrthoPediatrics Q2 revenue rose 15% to USD 70.5 million, driven by Trauma & Deformity growth.
• Net loss widened to USD 7.2 million, holding GAAP loss per share at USD 0.30.
• Adjusted EBITDA (non-GAAP) climbed 65% to USD 6.8 million; free cash flow used improved 78% to USD 3.1 million.
• Trauma & Deformity revenue jumped 26% to USD 52.6 million, while scoliosis revenue fell 9% to USD 16.9 million.
• Lifted full-year revenue outlook to USD 265 million-USD 269 million; expects about USD 25 million adjusted EBITDA (non-GAAP) and breakeven free cash flow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608041605PRIMZONEFULLFEED9803575) on August 04, 2026, and is solely responsible for the information contained therein.